1. Home
  2. Products
  3. Customized ADCs
  4. TNFRSF8
  5. Anti-TNFRSF8 (Brentuximab-LC-K149)-DBCO-MMAF ADC

Anti-TNFRSF8 (Brentuximab-LC-K149)-DBCO-MMAF ADC (CAT#: ADC-W-263)

This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (Brentuximab variant,LC-K149) conjugated via a DBCO linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • TNFRSF8
  • Alternative Names
  • TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
  • Target Entrez Gene ID
  • 943
  • Overview
  • The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
  • Overview
  • Anti-TNFRSF8-antibody, Brentuximab variant, LC-K149
  • Generic name
  • Brentuximab variant, LC-K149
  • Species Reactivity
  • Human
  • Name
  • DBCO (Dibenzocyclooctyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF (Monomethyl auristatin F)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-263. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2345 Anti-TNFRSF8 (Brentuximab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-1886 Anti-TNFRSF8 (Iratumumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2346 Anti-TNFRSF8 (Brentuximab )-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2347 Anti-TNFRSF8 (Brentuximab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1888 Anti-TNFRSF8 (Iratumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
CAT# Product Name Linker Payload
ADC-W-260 Anti-TNFRSF8 (Brentuximab-LC-N152)-DBCO-MMAF ADC DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F)
ADC-W-262 Anti-TNFRSF8 (Brentuximab-LC-E161)-DBCO-MMAF ADC DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F)
ADC-W-256 Anti-ERBB2 (Trastuzumab-LC-Q147)-DBCO-MMAF ADC DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F)
ADC-W-254 Anti-ERBB2 (Trastuzumab-LC-R142)-DBCO-MMAF ADC DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F)
ADC-W-252 Anti-TNFRSF8 (Brentuximab-HC-F126)-DBCO-MMAF ADC DBCO (Dibenzocyclooctyl) MMAF (Monomethyl auristatin F)
CAT# Product Name Linker Payload
ADC-W-491 Anti-TNFRSF17-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-AA-009 anti-HIgG(Fc)Fab-N-MMAF ADC Noncleavable linkers MMAF (Monomethyl auristatin F)
ADC-AA-027 anti-MIgG(Fc)Fab-N-MMAF ADC Noncleavable linkers MMAF (Monomethyl auristatin F)
ADC-W-493 Anti-CD19 (clone huB4)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-AA-002 anti-HIgG(Fc)-C-MMAF ADC Cleavable linkers MMAF (Monomethyl auristatin F)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.